Recap: Avid Bioservices Q2 Earnings

Shares of Avid Bioservices CDMO moved higher by 8.2% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 133.33% over the past year to $0.01, which beat the estimate of ($0.06).

Revenue of $21,064,000 up by 15.02% from the same period last year, which beat the estimate of $15,490,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Dec 02, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/jok7k959

Price Action

Company's 52-week high was at $9.37

52-week low: $3.02

Price action over last quarter: Up 11.76%

Company Profile

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.